Endocrine Evaluation and Homeostatic Model Assessment in Patients with Cornelia de Lange Syndrome

Ascaso, A. ; Latorre-Pellicer, A. (Universidad de Zaragoza) ; Puisac, B. (Universidad de Zaragoza) ; Trujillano, L. ; Arnedo, M. (Universidad de Zaragoza) ; Parenti, I. ; Llorente, E. ; Puente-Lanzarote, J. J. (Universidad de Zaragoza) ; Matute-LLorente, A. (Universidad de Zaragoza) ; Ayerza-Casas, A. (Universidad de Zaragoza) ; Kaiser, F. J. ; Ramos, F. J. (Universidad de Zaragoza) ; Pié, J. (Universidad de Zaragoza) ; Bueno-Lozano, G. (Universidad de Zaragoza)

Resumen: Objective: The aim of this study was to expand knowledge about endocrine disorders in individuals with Cornelia de Lange syndrome (CdLS), a rare developmental genetic disorder with anomalies in multiple organs and systems. Methods: Hormone levels, clinical scores, anthropometric measurements, and molecular analysis were assessed in 24 individuals with CdLS. Results: Hyperprolactinemia was the most common endocrine disorder. Three patients showed subclinical hypothyroidism. In the gonadotropic axis, mildly delayed puberty was observed, as well as genital anomalies, such as cryptorchidism. Despite short stature, levels of insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 were normal, on average. Three prepubertal individuals without risk factors had higher than normal values for the homeostatic model assessment of insulin resistance (HOMA-IR) and for insulinemia, suggesting insulin resistance. Furthermore, two adults had elevated BMIs associated with HOMA-IR values over the cut-off values. Conclusion: CdLS can lead to dysregulation of the endocrine system, particularly in patients with high HOMA-IR values and insulinemia who are at risk of insulin resistance. Therefore, clinical follow-ups with hormonal assessments are proposed for individuals with CdLS.

Idioma: Inglés

DOI: 10.4274/jcrpe.galenos.2022.2022-4-14

Año: 2022

Publicado en: JCRPE 16, 2 (2022), 211-217
ISSN: 1308-5727

Factor impacto JCR: 1.9 (2022)

Categ. JCR: PEDIATRICS rank: 74 / 130 = 0.569 (2022) - Q3 - T2
Categ. JCR: ENDOCRINOLOGY & METABOLISM rank: 128 / 144 = 0.889 (2022) - Q4 - T3

Factor impacto CITESCORE: 3.4 - Medicine (Q2) - Biochemistry, Genetics and Molecular Biology (Q3)

Factor impacto SCIMAGO: 0.502 - Pediatrics, Perinatology and Child Health (Q2) - Endocrinology (Q3) - Endocrinology, Diabetes and Metabolism (Q3)

Financiación: info:eu-repo/grantAgreement/ES/DGA/B32-17R
Financiación: info:eu-repo/grantAgreement/ES/DGA/B32-20R
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI19-01860

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Fisiología (Dpto. Farmac.Fisiol.y Med.L.F.)
Área (Departamento): Área Educación Física y Depor. (Dpto. Fisiatría y Enfermería)
Área (Departamento): Área Pediatría (Dpto. Microb.Ped.Radio.Sal.Pú.)